Gansu Province announced 182 kinds of low-priced drugs in the list of low-priced drugs during the year after the symposium on drug prices held by the National Development and Reform Commission and other departments. Prior to this, Guangdong has taken the lead in publicizing more than 400 low-priced drugs, and it is expected to be traded in December.

Experts on drug prices pointed out that, from the information from the recent price conference, China's drug prices will be reasonable, cracking down on artificially high prices, protecting low-priced drugs, and ensuring supply will be the main focus of China's drug price reform in 2014. Work.

According to the reporter's understanding, as early as July this year, the relevant leaders of the National Health and Family Planning Commission led a team to conduct research on how to solve the problem of high drug prices. The specific idea is: 17 national medical reform pilot cities and provincial-level Select several cities from the medical reform pilot cities to carry out price negotiation trials for drugs with sufficient market competition. If the results are obvious, they can be promoted on a large scale; jointly promote medical care, medical insurance, and medicine, and release the reform of drug policy and drug supply guarantee system. to a more important position.

"Some low-cost drugs have been repeatedly suppressed due to the bidding prices, resulting in too low profits and no one is willing to produce them." The relevant sales person in charge of Chen Liji Pharmaceutical Factory, a subsidiary of Baiyun Mountain, told reporters. It is reported that at the recent Guangdong Economic Development International Consultation Conference, Nobel Prize winner in Physiology and Medicine, Dr. Fried Murad, said that he has proposed to bring low-cost drugs back to the market. He said that the Chinese government now imposes retail price restrictions on low-priced drugs, which limits the development of low-priced drugs. "Because pharmaceutical factories cannot make profits from producing these drugs, they naturally have no incentive to produce them. Without profits, there is naturally no capital to invest in the research and development of higher * drugs. And the public cannot buy cheap drugs, so they can only switch to higher-priced alternatives. Drugs also increase the financial burden on patients. This is a vicious circle for pharmaceutical companies and patients.”

"Obviously, generic drug companies that can meet basic needs such as clinical drugs and have quality advantages will usher in new development opportunities," said a researcher in the pharmaceutical industry at a securities firm.